Device/Diagnostics Quarterly Deal Statistics, Q2 2014
Executive Summary
Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.
You may also be interested in...
Medtech Buyers Mull Mega-Mergers, Earn-Outs, And Google
Even with a surge in IPO opportunities, M&A remains the primary – almost exclusive – exit route for medtech investors and entrepreneurs. A panel of business development professionals speaking at the recent IN3 360° Boston conference presented insights on how start-ups might improve their chances of being acquired.
K2M Funds Its Focus On The Complex Spine With IPO
The 10-year-old spine firm initiated its initial public offering this month, transforming from the largest private spine device firm to another public player in a highly competitive market. CEO Eric Major says K2M’s focus on complex spinal deformities will help distinguish it from the pack.
More Mergers As A Direct Result Of Medtronic-Covidien Combo? Mixed Prospects
Medtronic’s massive acquisition of Covidien could accelerate the trend of industry consolidation further, some say. But executives from several big device firms insist nothing fundamental has changed.